Bariatric Surgery Devices Market (2026-2036)
The global Bariatric Surgery Devices Market was valued at USD 2.10 billion in 2025. This market is expected to reach USD 3.42 billion by 2036 from an estimated USD 2.18 billion in 2026, registering a CAGR of 4.6% during the forecast period (2026-2036).
- Published
- Sep 2026
- Pages
- 288
- Format
- PDF + Excel
- Report ID
- MR-2223
- Base year
- 2025
- 2025 · BASELINE
- $2.10B
- 2036
- $3.42B
- CAGR 2026–2036
- 4.6%
2025 baseline · 2026–2036 forecast at 4.6% CAGR · hover a bar for the value
Key highlights
The global Bariatric Surgery Devices Market is projected to reach USD 3.42 billion by 2036, driven by the undertreated obesity population, the durable outcomes of surgery, and expanded eligibility.
North America is expected to account for the largest market share in 2026, while Asia-Pacific is projected to register the fastest growth during the forecast period.
Surgical volumes are under pressure from GLP-1 medications. American College of Surgeons data presented at the American Society for Metabolic and Bariatric Surgery (ASMBS) meeting in May 2026 showed that just over 177,000 accredited-center procedures were performed in the U.S. in 2024, a 23% decline from a peak of more than 230,000 in 2022.
By product, Stapling Devices are expected to account for the largest market share, whereas Endoscopic Bariatric Devices are projected to witness the fastest growth through 2036.
Surgery remains the most effective treatment for severe obesity. A study of 51, 085 patients presented at the ASMBS 2025 meeting found that sleeve gastrectomy and gastric bypass produced 24% total weight loss after two years, compared with 4.7% for patients prescribed semaglutide or tirzepatide for at least six months.
Obesity remains vastly undertreated. According to the ASMBS, fewer than 1% of people eligible for metabolic and bariatric surgery undergo it in any given year, and an analysis of nearly 20 million U.S. patients with severe obesity found that 90% to 95% received no obesity treatment between 2018 and 2025.
Report summary
| Particulars | Details |
|---|---|
| Forecast Period | 2026-2036 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| CAGR (Value) | 4.6% |
| Format | PDF, Excel & Cloud Portal · 288 pages |
| Market Size (Value) in 2026 | USD 2.18 Billion |
| Market Size (Value) in 2036 | USD 3.42 Billion |
| Segments Covered | By Product: Stapling Devices, Energy Devices, Access Devices, Suturing Devices, Endoscopic Bariatric Devices, Intragastric Balloons, Gastric Bands, Robotic Instruments & Accessories. · By Procedure: Sleeve Gastrectomy, Roux-en-Y Gastric Bypass, Duodenal Switch & SADI-S, One-Anastomosis Gastric Bypass, Revisional Surgery, Endoscopic Procedures, Adjustable Gastric Banding. · By Approach: Laparoscopic, Robotic-Assisted, Endoscopic, Open. · By End User: Hospitals, Ambulatory Surgery Centers, Specialty Bariatric Centers. |
| Countries Covered | North America: U.S., Canada. · Europe: U.K., France, Germany, Italy, Spain, Nordic Countries, Rest of Europe. · Asia-Pacific: China, India, Japan, South Korea, Australia, Southeast Asia, Rest of Asia-Pacific. · Latin America: Brazil, Mexico, Colombia, Argentina, Chile, Rest of Latin America. · Middle East & Africa: Saudi Arabia, Kuwait, UAE & Qatar, Türkiye, Egypt, South Africa, Rest of Middle East & Africa. |
| Key Companies | Medtronic, Johnson & Johnson MedTech (Ethicon), Intuitive Surgical, Boston Scientific, Teleflex, Olympus, CONMED, Applied Medical, B. Braun, KARL STORZ, Cook Medical, Allurion Technologies, ReShape Lifesciences, Spatz Medical, Reach Surgical, and Fengh Medical. |
Report overview
Segments covered: product, procedure, approach, end user.
The growth of this market is mainly driven by the large and undertreated population living with severe obesity, the superior and durable weight loss achieved with metabolic and bariatric surgery, and expanded clinical eligibility for surgery under updated guidelines. However, the substitution of GLP-1 medications for surgery, reimbursement and access barriers, patient concerns about surgical risk and stigma, and the sharp decline in demand for intragastric balloons and gastric bands restrain the growth of this market.
Furthermore, revisional surgery after sleeve gastrectomy and failed medical therapy, endoscopic bariatric therapies, and rapidly growing procedure volumes in Asia-Pacific, Latin America, and the Middle East are expected to offer growth opportunities for the stakeholders in this market. However, uncertainty in procedure volumes, integrating surgery with GLP-1 treatment pathways, adapting to a changing procedure mix, and generating evidence for endoscopic therapies remain major challenges impacting the growth of this market. Additionally, the shift from sleeve gastrectomy toward gastric bypass, combined medical and surgical treatment pathways, the growth of robotic-assisted bariatric surgery, and the maturation of endoscopic therapies are prominent trends in this market.
The Bariatric Surgery Devices Market comprises the instruments, implants, and systems used to perform metabolic and bariatric procedures for the treatment of obesity and related metabolic diseases. The market covers surgical staplers and reloads, including manual, powered, and robotic staplers and staple-line reinforcement; energy-based vessel sealing and dissection devices; access devices such as trocars and liver retractors; suturing and closure devices; endoscopic bariatric devices used in endoscopic sleeve gastroplasty and related procedures; intragastric balloons; adjustable gastric bands; and robotic instruments and accessories used in bariatric surgery. Procedures include sleeve gastrectomy, Roux-en-Y gastric bypass, one-anastomosis gastric bypass, duodenal switch and single-anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S), revisional procedures, and endoscopic interventions. Robotic surgical system capital equipment and general surgical instruments not used in bariatric procedures are excluded. The ecosystem spans medical device manufacturers, robotic surgery companies, hospitals, ambulatory surgery centers, bariatric surgeons and gastroenterologists, payers, and professional societies.
The market is shaped by a large and largely untreated patient population. The World Health Organization estimated that 890 million adults were living with obesity in 2022. According to the ASMBS, 270,089 metabolic and bariatric procedures were performed in the U.S. in 2023, compared with 279,967 in 2022, yet fewer than 1% of eligible patients undergo surgery in any given year. An analysis of electronic health records from nearly 20 million U.S. patients with severe obesity, presented at the ASMBS 2026 meeting, found that 90% to 95% received no obesity treatment between 2018 and 2025. In 2022, the ASMBS and the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) updated their guidelines to recommend surgery for people with a body mass index of 35 or higher regardless of other conditions, and to consider it for those with a BMI of 30 to 34.9 with metabolic disease.
The rise of GLP-1 medications has reshaped demand. American College of Surgeons data presented in May 2026 showed U.S. procedures at accredited centers fell to just over 177,000 in 2024, down 23% from a peak of more than 230,000 in 2022, while GLP-1 prescriptions in the Epic Cosmos database rose from fewer than 4,600 in 2018 to more than 1.4 million in 2025. Intuitive Surgical reported that U.S. bariatric procedure volumes on its da Vinci systems declined at high single-digit rates for six consecutive quarters and now represent less than 3% of U.S. da Vinci procedures. At the same time, the procedure mix is shifting: sleeve gastrectomy fell from 64% to 58% of U.S. procedures between 2020 and 2024, while gastric bypass rose from 28% to 33%.
Clinical evidence continues to favor surgery for durable weight loss. A comparative effectiveness study of 51,085 patients from NYU Langone Health and NYC Health + Hospitals, presented at the ASMBS 2025 meeting, found that surgery patients lost 24% of their total body weight after two years, compared with 4.7% for patients prescribed GLP-1 medications for at least six months and 7% for those on continuous therapy for a full year. A further ASMBS 2026 study of more than 6,700 patients who used GLP-1s before surgery found that surgery continued to deliver substantial weight loss in this group, supporting the growing use of medications and surgery as complementary treatments.
Market dynamics
18 factors across 5 forcesLarge and Undertreated Population with Severe Obesity
The large and undertreated population living with severe obesity is a major factor driving the Bariatric Surgery Devices Market. The World Health Organization estimated that 890 million adults worldwide were living with obesity in 2022, and adult obesity has more than doubled since 1990. According to the ASMBS, fewer than 1% of people eligible for metabolic and bariatric surgery undergo it in any given year, and an analysis of electronic health records from nearly 20 million U.S. patients with severe obesity, presented at the ASMBS 2026 meeting, found that 90% to 95% received no obesity treatment of any kind between 2018 and 2025. Even with the rise of GLP-1 medications, the gap between the number of people who could benefit from surgery and those who receive it remains vast, providing a long-term base of demand for bariatric procedures and the devices used to perform them.
Superior and Durable Weight Loss with Surgery
The superior and durable weight loss achieved with metabolic and bariatric surgery is significantly supporting demand for surgical devices. A retrospective comparative effectiveness study of 51,085 patients with a body mass index of at least 35, conducted by NYU Langone Health and NYC Health + Hospitals and presented at the ASMBS 2025 meeting, found that patients who underwent sleeve gastrectomy or gastric bypass lost an average of 24% of their body weight after two years, compared with 4.7% for patients prescribed semaglutide or tirzepatide for at least six months. Even patients on continuous GLP-1 therapy for a full year lost only 7%, and the study's authors noted that as many as 70% of patients may discontinue GLP-1 treatment within a year. These results reinforce the role of surgery for patients with severe obesity and those who do not achieve or sustain adequate weight loss with medication.
Expanded Clinical Eligibility for Surgery
Expanded clinical eligibility for metabolic and bariatric surgery is broadening the addressable patient population. In 2022, the ASMBS and IFSO updated their joint guidelines, replacing criteria that had been in place since 1991, to recommend surgery for individuals with a body mass index of 35 or higher regardless of the presence of related conditions, to consider surgery for those with a BMI of 30 to 34.9 and metabolic disease, and to lower thresholds for Asian populations, for whom surgery should be considered from a BMI of 27.5. The guidelines also support surgery for appropriately selected adolescents. In the U.S., Medicare has covered certain bariatric procedures for eligible beneficiaries since 2006. Wider eligibility, combined with the undertreatment of obesity, increases the number of patients who could be referred for surgery over the forecast period.
Table of contents
12 chapters · 164 sections · 288 pages · click to expandSegmental analysis
| Segment | Largest share (2026) | Fastest growth (2026–2036) |
|---|---|---|
| By Product | Stapling Devices | Endoscopic Bariatric Devices |
| By Procedure | Sleeve Gastrectomy | Revisional Surgery |
| By Approach | Laparoscopic | Robotic-Assisted |
| By End User | Hospitals | Ambulatory Surgery Centers |
By Product
- The Stapling Devices segment is expected to account for the largest share of the market.
- The large share of this segment is mainly due to the use of multiple staple reloads and staple-line reinforcement in every sleeve gastrectomy, gastric bypass, and revisional procedure.
- However, the Endoscopic Bariatric Devices segment is projected to register the highest CAGR during the forecast period.
- The rapid growth of this segment is attributed to the FDA's 2022 indication for endoscopic sleeve gastroplasty, supporting clinical evidence, and demand for less invasive options.
By Procedure
- The Sleeve Gastrectomy segment is expected to account for the largest share of the market.
- The large share of this segment is mainly due to its position as the most commonly performed bariatric procedure, representing 58% of U.S. procedures in 2024.
- However, the Revisional Surgery segment is projected to register the highest CAGR during the forecast period.
- The rapid growth of this segment is attributed to conversions of prior sleeve gastrectomies and higher device utilization per case.
By Approach
- The Laparoscopic segment is expected to account for the largest share of the market.
- The large share of this segment is mainly due to its status as the standard of care for primary bariatric procedures worldwide.
- However, the Robotic-Assisted segment is projected to register the highest CAGR during the forecast period.
- The rapid growth of this segment is attributed to the shift toward gastric bypass and revisional procedures and the entry of new robotic surgical systems.
By End User
- The Hospitals segment is expected to account for the largest share of the market.
- The large share of this segment is mainly due to the concentration of accredited bariatric programs, inpatient capacity, and complex and revisional cases in hospital settings.
- However, the Ambulatory Surgery Centers segment is projected to register the highest CAGR during the forecast period.
- The rapid growth of this segment is attributed to growing outpatient sleeve gastrectomy and endoscopic procedures and efforts to reduce procedure costs.
Geographic analysis
North America
Largest shareIn 2026, North America is expected to account for the largest share of the global Bariatric Surgery Devices Market. The region's dominance is supported by the world's largest volume of bariatric procedures, extensive networks of accredited centers, and high adoption of advanced stapling and robotic technologies. According to the ASMBS, 270,089 metabolic and bariatric procedures were performed in the U.S. in 2023, although American College of Surgeons data show accredited-center volumes fell 23% between 2022 and 2024 as GLP-1 prescriptions grew to more than 1.4 million in the Epic Cosmos database in 2025. The U.S. is home to leading manufacturers including Medtronic, Johnson & Johnson MedTech, Intuitive Surgical, and Boston Scientific, and Medicare has covered bariatric surgery for eligible beneficiaries since 2006. Canada provides bariatric surgery through provincial health systems, where access is constrained by waiting lists. North America
Europe
Europe is expected to account for a significant share of the market. The World Health Organization's European Region reported in 2022 that 59% of adults were living with overweight or obesity, creating a large population eligible for treatment. Bariatric surgery is provided through public health systems in the U.K., France, Germany, Italy, Spain, and the Nordic countries, where volumes are constrained by budgets and waiting lists, and many systems do not reimburse GLP-1 medications for weight loss, which is expected to sustain demand for surgery relative to the U.S. Europe is also a center of surgical innovation, with European surgeons contributing to the development of one-anastomosis gastric bypass and SADI-S procedures, and IFSO co-authoring the 2022 international eligibility guidelines. Europe
Asia-Pacific
Fastest growthHowever, Asia-Pacific is projected to register the highest CAGR during the forecast period. The rapid growth of this region is attributed to large populations with obesity and type 2 diabetes, lower eligibility thresholds for Asian patients, and expanding surgical capacity. The 2022 ASMBS and IFSO guidelines recommend considering surgery for Asian patients from a body mass index of 27.5, significantly expanding the eligible population in China, India, Japan, South Korea, and Southeast Asia. China has a large and growing number of bariatric centers and domestic stapler manufacturers, India's private hospitals are expanding bariatric programs, and the high cost of GLP-1 medications relative to incomes in many Asian countries supports surgery as a long-term option. Asia-Pacific
Latin America
Latin America is expected to account for a significant share of the market, led by Brazil and Mexico. Brazil is one of the world's leading countries for bariatric surgery volumes, with procedures covered by both private insurance and the public Unified Health System, and Mexico, where more than a third of adults are living with obesity, has an active bariatric surgery sector that also serves medical tourists from the U.S. Colombia, Argentina, and Chile have growing numbers of bariatric centers. The high cost of GLP-1 medications relative to regional incomes supports continued demand for surgery as a durable, one-time intervention. Affordability of GLP-1 medications is a key constraint in the region: Novo Nordisk reported that sales in its Emerging Markets region, which includes Latin America, fell 18% at constant exchange rates in the first quarter of 2026 amid competition and pricing pressure, while the 2022 ASMBS and IFSO guidelines support surgery for patients with a body mass index of 35 or higher, and from 30 with metabolic disease. Latin America
Middle East & Africa
The Middle East & Africa is expected to register strong growth. Gulf countries, including Kuwait, Saudi Arabia, Qatar, and the UAE, have some of the world's highest rates of obesity, with adult obesity approaching or exceeding 35% in several states according to WHO data, and have developed high-volume bariatric surgery programs, particularly for sleeve gastrectomy. Government-funded healthcare in the Gulf and investment in specialized surgical centers support device demand, while Türkiye has become a regional hub for bariatric surgery and medical tourism, and South Africa and Egypt are expanding bariatric services. Under the 2022 ASMBS and IFSO guidelines, surgery is recommended for patients with a body mass index of 35 or higher and considered from 30 with metabolic disease, thresholds that a large share of adults in the Gulf exceed, and Novo Nordisk's Emerging Markets region, which includes the Middle East and Africa, recorded an 18% decline in sales at constant exchange rates in the first quarter of 2026, reflecting the affordability limits of branded GLP-1 therapy. Middle East & Africa
Competitive landscape
The global Bariatric Surgery Devices Market is moderately consolidated, with a small number of large medical device companies leading surgical stapling and energy devices, robotic surgery companies supplying instruments and staplers for robotic procedures, endoscopy companies offering endoscopic bariatric systems, and specialized companies focused on intragastric balloons, gastric bands, and bariatric-specific instruments. Competition centers on stapling reliability and staple-line security, powered and smart stapling technologies, integration with robotic platforms, clinical evidence, surgeon training, and pricing to hospitals and group purchasing organizations.
Leading companies are investing in powered and robotic stapling, staple-line reinforcement, endoscopic suturing, and surgeon education, while adapting portfolios to lower overall volumes and a shift toward gastric bypass and revisional surgery. Boston Scientific's acquisition of Apollo Endosurgery in 2023 illustrates consolidation in endoscopic bariatric therapies.
The report provides a comprehensive competitive assessment of the leading companies operating in the global Bariatric Surgery Devices Market. The key players profiled in the report include Medtronic plc (Ireland), Johnson & Johnson MedTech (Ethicon) (U.S.), Intuitive Surgical, Inc. (U.S.), Boston Scientific Corporation (U.S.), Teleflex Incorporated (U.S.), Olympus Corporation (Japan), CONMED Corporation (U.S.), Applied Medical Resources Corporation (U.S.), B. Braun Melsungen AG (Germany), KARL STORZ SE & Co. KG (Germany), Cook Medical LLC (U.S.), Allurion Technologies, Inc. (U.S.), ReShape Lifesciences Inc. (U.S.), Spatz Medical (U.S.), Reach Surgical, Inc. (China), and Fengh Medical Co., Ltd. (China).
- Medtronic
- Johnson & Johnson MedTech · Ethicon
- Intuitive Surgical
- Boston Scientific
- Teleflex
- Olympus
- CONMED
- Applied Medical
- B. Braun
- KARL STORZ
- Cook Medical
- Allurion Technologies
- ReShape Lifesciences
- Spatz Medical
- Reach Surgical
- Fengh Medical
Expert perspectives
Bariatric surgery is at a turning point. GLP-1 medications have reduced U.S. procedure volumes at accredited centers by 23% from their 2022 peak and cut intragastric balloon procedures by about two-thirds in a single year, yet surgery still delivers roughly five times the weight loss of real-world GLP-1 therapy, and fewer than 1% of eligible patients undergo it. The market is therefore not disappearing, but reshaping around new patient pathways.
Three structural changes are expected to shape the market through 2036. First, surgery will increasingly serve patients who do not achieve or sustain results with medication, making it a later-line but more complex intervention, with more gastric bypass and revisional procedures. Second, robotic and powered stapling will capture a growing share of procedures as complexity rises. Third, growth will shift toward Asia-Pacific, Latin America, and the Middle East, where obesity is rising rapidly, eligibility thresholds are lower for Asian patients, and GLP-1 medications remain costly.
For companies planning entry or expansion, the most attractive positions over the forecast period are likely to be found in advanced and robotic stapling for bypass and revisional surgery, endoscopic suturing platforms supported by strong clinical evidence, and emerging-market bariatric programs. The principal risks are continued volume declines from GLP-1 substitution, reimbursement barriers, and uncertainty in forecasting demand.
Customer perspectives
Insights gathered during primary interviews with bariatric surgeons, hospital supply chain leaders, and gastroenterologists highlight where purchasing priorities are shifting. The following perspectives reflect recurring themes raised across these discussions.
“This reflects the shift toward complex procedures and higher device value per case.”
“This indicates price and value pressure on device suppliers in a lower-volume environment.”
“This points to reimbursement as the key lever for endoscopic bariatric therapies.”
Frequently asked questions
The global Bariatric Surgery Devices Market is estimated at USD 2.18 billion in 2026.
Cite this report
Meticulous Research. (2026). Bariatric Surgery Devices Market - Global Opportunity Analysis and Industry Forecast (2026-2036) (Report No. MR-2223). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/reports/bariatric-surgery-devices-market-6906